Pancreatic ductal adenocarcinoma (PDAC) exhibits extensive inter- and intratumoral heterogeneity, along with a significant stromal component. This protocol outlines steps to generate patient-derived xenografts (PDXs), isolate and enrich human PDAC epithelial cells, and verify their identity using droplet digital PCR (ddPCR) and human-specific markers. It provides a robust approach for culturing cancer epithelial cells to develop a human PDAC model system. For complete details on the use and execution of this protocol, please refer to Grygoryev et al..
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.xpro.2025.103672 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor.
Cells
February 2025
Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
Patient-derived xenograft (PDX) models are powerful tools in cancer research, offering an accurate platform for evaluating cancer treatment efficacy and predicting responsiveness. However, these models necessitate surgical techniques for tumor tissue transplantation and face challenges with non-uniform tumor growth among animals. To address these issues, we attempted to develop a new PDX modeling method using high-grade serous ovarian cancer (HGSC), a fatal disease with a 5-year survival rate of 29%, which requires personalized research due to its morphological, genetic, and molecular heterogeneities.
View Article and Find Full Text PDFBreast cancer preclinical models: a vital resource for comprehending disease mechanisms and therapeutic development.
EXCLI J
February 2025
Interdisciplinary Center for Innovation in Biotechnology and Neuroscience, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, 10250, Sri Lanka.
A significant obstacle in translating innovative breast cancer treatments from bench to bed side is demonstrating efficacy in preclinical settings prior to clinical trials, as the heterogeneity of breast cancer can be challenging to replicate in the laboratory. A significant number of potential medicines have not progressed to clinical trials because preclinical models inadequately replicate the complexities of the varied tumor microenvironment. Consequently, the variety of breast cancer models is extensive, and the selection of a model frequently depends on the specific inquiry presented.
View Article and Find Full Text PDFRapid and Effective Neuronal Conversion of Human Glioblastoma In Vitro and In Vivo Using Potent Small Molecules.
Cell Prolif
March 2025
Department of Cell Biology, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China.
Exploring effective, prompt and universally applicable approaches for inducing the differentiation of glioblastoma (GBM) into terminally differentiated cells, such as astrocytes or neurons that cease cell division, is pivotal for the success of GBM differentiation therapy. In this study, a neuronal-specific promoter-reporter system was employed to screen small molecules that promote neural differentiation. The cocktail YFSS, consisting of Y27632, Forskolin, SB431542 and SP600125, which selectively targets the ROCK, cAMP, TGF-β and JNK signalling pathways, respectively, was found to effectively trigger differentiation in human GBM cells.
View Article and Find Full Text PDFUnveiling radiobiological traits and therapeutic responses of BRAF-mutant colorectal cancer via patient-derived organoids.
J Exp Clin Cancer Res
March 2025
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background: Radiotherapy (RT) is an essential treatment for colorectal cancer (CRC), yet the factors influencing radiosensitivity remain unclear. In the quest to enhance the therapeutic efficacy in CRC, the interplay between genetic mutations and RT sensitivity has emerged as a pivotal yet enigmatic area.
Methods: We harness the fidelity of patient-derived organoids (PDOs) to dissect the molecular landscape of radiosensitivity, with a particular emphasis on BRAF mutations.
Homologous recombination deficiency (HRD) contributes to genomic instability and leads to sensitivity to poly ADP-ribose polymerase inhibitors (PARPi). HRD also activates the cyclic GMP-AMP synthase (cGAS)-STimulator of INterferon Genes (STING)-Interferon (IFN) pathway, highlighting the need to understand the impact of cGAS-STING-IFN signaling on PARPi efficacy. In this study, we analyzed a cohort of thirty-five breast cancer (BC) patient-derived xenografts (PDX) and mouse-derived allografts (MDA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!